secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001493152-26-009299
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona reports building ZEVASKYN launch momentum; payer coverage reaches 80% of commercial lives
--------------------------------------------------------------------------------

- First patient treated with ZEVASKYN in Dec 2025; manufacturing resumed Jan 2026, multiple biopsies collected, additional scheduled.
- All major commercial payers (United Healthcare, Cigna, Aetna, Anthem, most BCBS) now cover ZEVASKYN, representing ~80% of commercial lives.
- CMS established permanent HCPCS J-code (J3389) effective Jan 1, 2026; coverage also secured across all Medicaid programs.
- Initial Qualified Treatment Centers gaining familiarity with administrative processes; growing patient and physician interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315226009299/0001493152-26-009299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315226009299/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer